Low-dose growth hormone therapy reduces inflammation in HIV-infected patients: a randomized placebo-controlled study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Low-dose growth hormone therapy reduces inflammation in HIV-infected patients : a randomized placebo-controlled study. / Lindboe, Johanne Bjerre; Langkilde, Anne; Eugen-Olsen, Jesper; Hansen, Birgitte R.; Haupt, Thomas H.; Petersen, Janne; Andersen, Ove.
I: Infectious diseases (London, England), Bind 48, Nr. 11-12, 2016, s. 829-837.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Low-dose growth hormone therapy reduces inflammation in HIV-infected patients
T2 - a randomized placebo-controlled study
AU - Lindboe, Johanne Bjerre
AU - Langkilde, Anne
AU - Eugen-Olsen, Jesper
AU - Hansen, Birgitte R.
AU - Haupt, Thomas H.
AU - Petersen, Janne
AU - Andersen, Ove
PY - 2016
Y1 - 2016
N2 - BACKGROUND: Combination antiretroviral therapy (cART) has drastically increased the life expectancy of HIV-infected patients. However, HIV-infected patients exhibit increased inflammation and 33-58% exhibit a characteristic fat re-distribution termed HIV-associated lipodystrophy syndrome (HALS). Recombinant human growth hormone (rhGH) has been tested as treatment of HALS. Low-dose rhGH therapy improves thymopoiesis and fat distribution in HIV-infected patients and appears to be well tolerated. However, since high-dose rhGH is associated with adverse events related to inflammation, we wanted to investigate the impact of low-dose rhGH therapy on inflammation in HIV-infected patients.METHODS: Forty-six cART-treated HIV-infected men were included in the HIV-GH low-dose (HIGH/Low) study: a randomized, placebo-controlled, double-blinded trial. Subjects were randomized 3:2 to 0.7 mg/day rhGH, or placebo for 40 weeks. rhGH was self-administered between 1 pm and 3 pm. The primary outcome of this substudy was changes in inflammation measured by plasma C-reactive protein (CRP) and soluble urokinase plasminogen activator receptor (suPAR).RESULTS: Both CRP (-66%, p = 0.002) and suPAR (-9.7%, p = 0.06) decreased in the rhGH group compared to placebo; however, only CRP decreased significantly. The effect of rhGH on inflammation was not mediated through rhGH-induced changes in insulin-like growth factor 1, body composition, or immune parameters.CONCLUSION: Daily 0.7 mg rhGH treatment for 40 weeks, administered at nadir endogenous GH secretion, significantly reduced CRP. The effect does not appear to be mediated by other factors. Our findings suggest that low-dose rhGH treatment may minimize long-term risks associated with high-dose rhGH therapy.
AB - BACKGROUND: Combination antiretroviral therapy (cART) has drastically increased the life expectancy of HIV-infected patients. However, HIV-infected patients exhibit increased inflammation and 33-58% exhibit a characteristic fat re-distribution termed HIV-associated lipodystrophy syndrome (HALS). Recombinant human growth hormone (rhGH) has been tested as treatment of HALS. Low-dose rhGH therapy improves thymopoiesis and fat distribution in HIV-infected patients and appears to be well tolerated. However, since high-dose rhGH is associated with adverse events related to inflammation, we wanted to investigate the impact of low-dose rhGH therapy on inflammation in HIV-infected patients.METHODS: Forty-six cART-treated HIV-infected men were included in the HIV-GH low-dose (HIGH/Low) study: a randomized, placebo-controlled, double-blinded trial. Subjects were randomized 3:2 to 0.7 mg/day rhGH, or placebo for 40 weeks. rhGH was self-administered between 1 pm and 3 pm. The primary outcome of this substudy was changes in inflammation measured by plasma C-reactive protein (CRP) and soluble urokinase plasminogen activator receptor (suPAR).RESULTS: Both CRP (-66%, p = 0.002) and suPAR (-9.7%, p = 0.06) decreased in the rhGH group compared to placebo; however, only CRP decreased significantly. The effect of rhGH on inflammation was not mediated through rhGH-induced changes in insulin-like growth factor 1, body composition, or immune parameters.CONCLUSION: Daily 0.7 mg rhGH treatment for 40 weeks, administered at nadir endogenous GH secretion, significantly reduced CRP. The effect does not appear to be mediated by other factors. Our findings suggest that low-dose rhGH treatment may minimize long-term risks associated with high-dose rhGH therapy.
KW - Adult
KW - Anti-Retroviral Agents
KW - C-Reactive Protein
KW - Double-Blind Method
KW - Drug Therapy, Combination
KW - Growth Hormone
KW - HIV Infections
KW - Humans
KW - Inflammation
KW - Male
KW - Middle Aged
KW - Placebos
KW - Receptors, Urokinase Plasminogen Activator
KW - Treatment Outcome
KW - Young Adult
KW - Journal Article
KW - Randomized Controlled Trial
U2 - 10.1080/23744235.2016.1201722
DO - 10.1080/23744235.2016.1201722
M3 - Journal article
C2 - 27417288
VL - 48
SP - 829
EP - 837
JO - Infectious Diseases
JF - Infectious Diseases
SN - 2374-4235
IS - 11-12
ER -
ID: 176836069